INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
2.560
-0.170 (-6.23%)
At close: Aug 1, 2025, 4:00 PM
2.600
+0.040 (1.56%)
After-hours: Aug 1, 2025, 7:48 PM EDT

Accolade Stock Forecast

Stock Price Forecast

The 3 analysts that cover Accolade stock have a consensus rating of "Buy" and an average price target of $9.53, which forecasts a 272.27% increase in the stock price over the next year. The lowest target is $0.60 and the highest is $20.

Price Target: $9.53 (+272.27%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$0.60$9.53$8.00$20
Change-76.56%+272.27%+212.50%+681.25%
* Price targets were last updated on Jul 2, 2025.

Analyst Ratings

The average analyst rating for Accolade stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingFeb '25Mar '25Apr '25May '25Jun '25Jul '25
Strong Buy222222
Buy111110
Hold000001
Sell000001
Strong Sell000000
Total333334

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Maxim Group
Maxim Group
Strong Buy
Maintains
$30$8
Strong BuyMaintains$30$8+212.50%Jul 2, 2025
BTIG
BTIG
Hold
Downgrades
n/a
HoldDowngradesn/an/aJul 1, 2025
Scotiabank
Scotiabank
Sell
Downgrades
$23$0.6
SellDowngrades$23$0.6-76.56%Jul 1, 2025
Maxim Group
Maxim Group
Strong Buy
Maintains
$22$30
Strong BuyMaintains$22$30+1,071.88%Feb 13, 2025
Scotiabank
Scotiabank
Buy
Maintains
$22$23
BuyMaintains$22$23+798.44%Feb 11, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
43.72K
from 14.00K
Increased by 212.27%
Revenue Next Year
4.50M
from 43.72K
Increased by 10,184.28%
EPS This Year
-1.59
from -2.11
EPS Next Year
-1.41
from -1.59
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
11.00K181.00K374.00K155.00K14.00K43.72K4.50M13.07M
Revenue Growth
-1,545.46%106.63%-58.56%-90.97%212.27%10,184.28%190.75%
EPS
-1.01-1.88-1.52-1.67-2.11-1.59-1.41-1.30
EPS Growth
--------
Forward PE
--------
No. Analysts
-----887
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20252026202720282029
High105,00015.2M24.8M
Avg43,7174.5M13.1M
Lown/an/an/a

Revenue Growth

Revenue Growth20252026202720282029
High
650.0%
34,577.4%
451.2%
Avg
212.3%
10,184.3%
190.7%
Low---

EPS Forecast

EPS20252026202720282029
High-1.49-0.53-0.83
Avg-1.59-1.41-1.30
Low-1.81-2.11-1.62

EPS Growth

EPS Growth20252026202720282029
High---
Avg---
Low---
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.